Doré copper annonce la clôture du placement de droits
January 02, 2024 07:30 ET
|
DORÉ COPPER MINING CORP
Ne pas distribuer aux agences de presse des États-Unis ni diffuser aux États-Unis. TORONTO, 02 janv. 2024 (GLOBE NEWSWIRE) -- Doré Copper Mining Corp. (la « Société » ou « Doré Copper ») (TSXV :...
Doré Copper Announces Closing Of Rights Offering
January 02, 2024 07:30 ET
|
DORÉ COPPER MINING CORP
Not for distribution to United States news wire services or for dissemination in the United States TORONTO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Doré Copper Mining Corp. (the "Corporation" or "Doré...
Doré Copper annonce un placement de droits
November 21, 2023 08:49 ET
|
DORÉ COPPER MINING CORP
Ne pas distribuer aux agences de presse des États-Unis ni diffuser aux États-Unis. TORONTO, 21 nov. 2023 (GLOBE NEWSWIRE) -- Doré Copper Mining Corp. (la « Société » ou « Doré Copper ») (TSXV :...
Doré Copper Announces Rights Offering
November 21, 2023 08:49 ET
|
DORÉ COPPER MINING CORP
Not for distribution to United States news wire services or for dissemination in the United States TORONTO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Doré Copper Mining Corp. (the "Corporation" or "Doré...
Denarius Metals Announces Closing of Rights Offering
March 02, 2023 14:34 ET
|
Denarius Metals Corp.
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, March 02, 2023 (GLOBE NEWSWIRE) -- Denarius Metals Corp. (“Denarius Metals” or the...
Denarius Metals Announces Rights Offering
January 16, 2023 07:00 ET
|
Denarius Metals Corp.
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Denarius Metals Corp. (“Denarius Metals” or “the...
Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody
December 06, 2022 07:30 ET
|
Summit Therapeutics Inc.
Menlo Park, California, US, and Grand Cayman, Cayman Islands, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced a...
Persbericht Biocartis Group NV: Biocartis lanceert een aandelenuitgifte met voorkeurrecht (met extralegale voorkeurrechten voor bestaande aandeelhouders) van maximaal 33.476.932 aangeboden aandelen,ten bedrage van maximaal EUR 25.107.699,00
November 16, 2022 01:00 ET
|
Biocartis NV
ADVERTENTIE PERSBERICHT: VOORKENNIS / GEREGLEMENTEERDE INFORMATIE16 november 2022, 07:00 CET Biocartis lanceert een aandelenuitgifte met voorkeurrecht (met extralegale voorkeurrechten voor bestaande...
Press release Biocartis Group NV: Biocartis launches a rights offering (with extra-legal preferential rights for existing shareholders) of a maximum of 33,476,932 offered shares, amounting to a maximum of EUR 25,107,699.00
November 16, 2022 01:00 ET
|
Biocartis NV
ADVERTISEMENT PRESS RELEASE: INSIDE INFORMATION / REGULATED INFORMATION 16 November 2022, 07:00 CET Biocartis launches a rights offering (with extra-legal preferential rights for existing...
Summit Therapeutics Closes Fully-Subscribed $100 Million Rights Offering
August 09, 2022 13:37 ET
|
Summit Therapeutics Inc.
Menlo Park, California, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today announced the successful closing of its fully-subscribed...